BiotechTube

Placebo + Elagolix

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Endometriosis, Pain

Conditions

Endometriosis, Pain

Trial Timeline

Oct 12, 2009 → Sep 22, 2010

NCT ID
NCT00973973

About Placebo + Elagolix

Placebo + Elagolix is a phase 2 stage product being developed by AbbVie for Endometriosis, Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT00973973. Target conditions include Endometriosis, Pain.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00973973Phase 2Completed

Competing Products

20 competing products in Endometriosis, Pain

See all competitors
ProductCompanyStageHype Score
ASP1707 + Placebo + Leuprorelin acetateAstellas PharmaPhase 2
52
40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetateSumitomo PharmaPhase 3
77
SHR7280 TabletsJiangsu Hengrui MedicinePhase 1
33
SHR7280 tablets + SHR7280 dry suspensionJiangsu Hengrui MedicinePhase 1
33
SHR7280 + Placebo oral tabletJiangsu Hengrui MedicinePhase 1/2
41
SHR7280 Tablet + SHR7280 Placebo TabletJiangsu Hengrui MedicinePhase 1
33
Elagolix + Placebo + Combined Oral ContraceptiveAbbViePhase 3
77
Estradiol/Norethindrone Acetate + Placebo for Elagolix + Elagolix + Placebo for E2/NETAAbbViePhase 3
77
ElagolixAbbViePhase 3
77
elagolix + estradiol/norethindrone acetate (E2/NETA)AbbViePhase 3
77
Elagolix + placeboAbbViePhase 2
52
ElagolixAbbViePhase 3
77
Elagolix + Subcutaneous depot medroxyprogesterone acetate (DMPA-SC) + Placebo to Elagolix + Placebo to DMPA-SCAbbViePhase 2
52
elagolixAbbViePhase 3
77
ElagolixAbbViePhase 3
77
Leuprorelin Acetate Depot + Elagolix + Placebo to Elagolix + Placebo to Leuprorelin AcetateAbbViePhase 2
52
Gefapixant + Placebo + NaproxenMerckPhase 2
52
BGS649 + PlaceboNovartisPhase 2
52
Active treatment with a high dose of BGS649 + Active treatment with a low dose of BGS649 + Placebo treatment to blind studyNovartisPhase 2
52
LetrozoleNovartisPhase 2
52

Other Products from AbbVie

Pancrelipase + PancrelipaseApproved
85
CREONApproved
85
Venetoclax + AzacitidineApproved
85
Oxybutynin + PlaceboApproved
85
Glecaprevir-pibrentasvirApproved
85